Financhill
Back

Arcturus Therapeutics Holdings Quote, Financials, Valuation and Earnings

Buy
64

ARCT
Arcturus Therapeutics Holdings

Last Price:
30.53
Seasonality Move:
25.77%

7 Day Trial

ALL ACCESS PASS

$ 7

Arcturus Therapeutics Holdings Price Quote

$30.53
+0.03 (+5.22%)
(Updated: May 17, 2024 at 5:32 AM ET)

Arcturus Therapeutics Holdings Key Stats

Buy
64
Arcturus Therapeutics Holdings (ARCT) is a Buy

Day range:
$28.86 - $30.99
52-week range:
$17.52 - $43.81
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
7.37
P/B ratio:
3.11%

Volume:
347.5K
Avg. volume:
494.6K
1-year change:
7.21%
Market cap:
$821.4M
Revenue:
$157.7M
EPS:
$-3.91

How Much Does Arcturus Therapeutics Holdings Make?

Is Arcturus Therapeutics Holdings Growing As A Company?

Arcturus Therapeutics Holdings Stock Price Performance

What Is Arcturus Therapeutics Holdings 52-Week High & Low?

Arcturus Therapeutics Holdings Price To Free Cash Flow

Is It Risky To Buy Arcturus Therapeutics Holdings?

Is Arcturus Therapeutics Holdings Cash Flow Positive?

Arcturus Therapeutics Holdings Return On Invested Capital

  • Is Management Doing A Good Job?
    ARCT return on invested capital is -36.82%
  • What Is Arcturus Therapeutics Holdings Return On Assets?
    ROA measures how assets are converting to revenues and is -24.3%
  • What Is ARCT Return On Equity?
    ROE is a measure of profitability and is -37.33%

Arcturus Therapeutics Holdings Earnings Date & Stock Price

Arcturus Therapeutics Holdings Competitors

Arcturus Therapeutics Holdings Dividend Yield

Data Unavailable

Arcturus Therapeutics Holdings Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 12.59%
Revenue: -59.11% 115.09%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 72.29
Upside from Last Price: 137.02%

Major Shareholders

  • How many ARCT shares are owned by institutional investors?
    49.3M ARCT shares are owned by institutional investors
  • How many ARCT shares are owned by insiders?
    2.3M ARCT shares are owned by insiders